Every 10-Q that GLOBAL INNOVATIVE PLATFOM (GIPL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GIPL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GIPL filings page.
Global Innovative Platforms Inc., a pre-revenue-stage animal health diagnostics company focused on breath analysis under its VetBreath Analytics brand, reported its first commercial revenues while remaining unprofitable for the quarter and nine months ended June 30, 2026.
The company generated $50,700 in revenue for the quarter and $187,200 for the nine months, all from a single contract with a leading global animal health company using its VetBreath Dx technology. Net losses were $241,611 for the quarter and $442,425 for the nine months, compared with losses of $211,818 and $483,635 in the prior-year periods. Cash and cash equivalents increased to $244,235, with total assets of $539,261 and minimal liabilities of $7,791, resulting in stockholders’ equity of $531,470. Operations were financed primarily through common stock issuances, including $620,000 raised in cash and 2,794,000 shares issued for services during the nine months.
Management discloses a going concern uncertainty due to limited revenue, accumulated deficit of $1,697,889, and dependence on raising additional capital. The business is also concentrated around a key Patent and Know-How License Agreement with Defiant Technologies, which requires milestone payments and a 3% royalty on net sales. Internal control over financial reporting is not effective, with material weaknesses in accounting expertise, segregation of duties, and spreadsheet controls. FINRA processed a Form 211 to allow priced quotations in the stock, but the existence of an active market is not assured.
Global Innovative Platforms Inc. reported its first revenues while remaining deeply loss-making and dependent on new funding. For the quarter ended March 31, 2026, the company generated $106,500 in revenue, all from a single animal-health customer using its VOCAM Plus diagnostic technology, and posted a net loss of $151,386. For the six-month period, revenue totaled $136,500 with a net loss of $200,815. Cash and cash equivalents rose to $327,270 and total assets to $591,958, largely funded by $514,354 of common stock proceeds, while liabilities stayed minimal at $2,284. The accumulated deficit reached $1,456,279, and management and the auditors highlight substantial doubt about the company’s ability to continue as a going concern without additional debt or equity financing. As of May 15, 2026, there were 49,103,241 common shares outstanding, reflecting continued equity issuance to investors and service providers.
Global Innovative Platforms Inc. reported its quarterly results for the three months ended December 31, 2025. The animal health diagnostics company generated its first revenue, recording $30,000 from a licensing and evaluation agreement for its Plus breath-analysis technology, but still posted a net loss of $49,429, improved from a $120,467 loss a year earlier. Operating expenses fell as research and development and general and administrative costs declined, helping narrow losses.
Cash and cash equivalents were $49,004 with total assets of $224,951 and current liabilities of $65,784, including $55,500 of deferred revenue tied to its new contract. Accumulated deficit reached $1,304,892, and management again disclosed “substantial doubt” about the company’s ability to continue as a going concern, noting it will need additional debt or equity financing to fund operations and growth. As of February 17, 2026, 47,531,657 common shares were outstanding, reflecting ongoing equity issuance to fund the business.